Evidence map›Paper›PMID 36686417›Full record

ArticleFrontiers in endocrinology2022

A clinical prediction model for predicting the risk of liver metastasis from renal cell carcinoma based on machine learning.

Ziye Wang, Chan Xu, Wencai Liu, Meiying Zhang, Jian'an Zou, Mingfeng Shao, Xiaowei Feng, Qinwen Yang, Wenle Li, Xiue Shi and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Navigating advanced renal cell carcinoma in the era of artificial intelligence.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 2 countries.

Ziye WangDepartment of Urology, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, China.
Chan XuClinical Medical Research Center, Xianyang Central Hospital, Xianyang, China.
Wencai LiuDepartment of Orthopaedic Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Meiying ZhangDepartment of Gastroenterology and Hepatology, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
Jian'an ZouDepartment of Urology, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, China.
Mingfeng ShaoDepartment of Urology, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, China.
Xiaowei FengDepartment of Neuro Rehabilitation, Shaanxi Provincial Rehabilitation Hospital, Xi'an, China.
Qinwen YangSchool of Computer Science and Engineering, North Minzu University, Yinchuan, China.
Wenle LiDepartment of Neuro Rehabilitation, Shaanxi Provincial Rehabilitation Hospital, Xi'an, China.
Xiue ShiDepartment of Geriatrics, Shaanxi Provincial Rehabilitation Hospital, Xi'an, China.
Guangxi ZangFaculty of Medicine, Macau University of Science and Technology, Macau, Macao SAR, China.
Chengliang YinFaculty of Medicine, Macau University of Science and Technology, Macau, Macao SAR, China.
Anhui University of Traditional Chinese Medicine · CNMacau University of Science and Technology · MOChinese People's Liberation Army · CNNanchang University · CNNorth Minzu University · CNXiamen University · CNXian Yang Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Renal cell carcinoma (RCC) is a highly metastatic urological cancer. RCC with liver metastasis (LM) carries a dismal prognosis. The objective of this study is to develop a machine learning (ML) model that predicts the risk of RCC with LM, which is used to assist clinical treatment. Methods: The retrospective study data of 42,547 patients with RCC were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. ML includes algorithmic methods and is a fast-rising field that has been widely used in the biomedical field. Logistic regression (LR), Gradient Boosting Machine (GBM), Extreme Gradient Boosting (XGB), random forest (RF), decision tree (DT), and naive Bayesian model [Naive Bayes Classifier (NBC)] were applied to develop prediction models to predict the risk of RCC with LM. The six models were 10-fold cross-validated, and the best-performing model was selected based on the area under the curve (AUC) value. A web online calculator was constructed based on the best ML model. Results: Bone metastasis, lung metastasis, grade, T stage, N stage, and tumor size were independent risk factors for the development of RCC with LM by multivariate regression analysis. In addition, the correlation of the relative proportions of the six clinical variables was shown by a heat map. In the prediction models of RCC with LM, the mean AUC of the XGB model among the six ML algorithms was 0.947. Based on the XGB model, the web calculator (https://share.streamlit.io/liuwencai4/renal_liver/main/renal_liver.py) was developed to evaluate the risk of RCC with LM. Conclusions: This XGB model has the best predictive effect on RCC with LM. The web calculator constructed based on the XGB model has great potential for clinicians to make clinical decisions and improve the prognosis of RCC patients with LM.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsLiver NeoplasmsBayes TheoremHumansMachine LearningModels, StatisticalPrognosisRetrospective Studiesliver metastasismachine learningprognostic factorsrenal cell carcinomaweb calculator

Identifiers

PMID36686417
PMCPMC9850289
OpenAlexW4313555521

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.